Hexima (HXL) Stock Price, News & Analysis

Company Overview

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company's lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $2.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Chemicals
• Current Symbol: ASX:HXL
• CIK: N/A
• Web: hexima.com.au
• Phone: 61-3-9479-1210
• Fax: N/A
• Employees: 5,330
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: -1,169.86%
• Pretax Margin: N/A
• Return on Equity: -51.21%
• Return on Assets: -12.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.12
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 167,040,000
• Free Float: N/A
• Market Cap: $2.17 million
• Optionable: N/A
• Beta: 0.79